Merck, Eisai to discontinue late-stage study for skin cancer
Improvement in overall survival was one of the study's dual main goals, according to Merck and Eisai
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Eisai
USFDA accepts Eisai’s sBLA and grants priority review for approval of LEQEMBITM…
USFDA accepts Eisai's sBLA and grants priority review for approval of LEQEMBITM Alzheimer's treatment
Eisai files for approval of Alzheimer’s drug in Japan
The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called…
Eisai files for approval of Alzheimer’s drug in Europe
The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called…
Roche’s Alzheimer’s drug fails to meet goal in long awaited trial
The Swiss drugmaker conducted two identically designed studies, each with about 1,000 participants, who were examined and queried…
Biogen raises annual profit forecast for second straight quarter
Data on the drug has been promising and Biogen and Eisai are expected to file for a US approval soon with a decision expected in…
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective 1st…
Dr Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals to sell its…
In March 2016, Dr Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer…
Eisai, Bristol Myers Squibb enter collaboration for Eisai’s MORAb-202 antibody-drug conjugate
The companies are planning to move into the registrational stage of development for this asset as early as next year
Biogen applies for approval of Alzheimer’s drug, aducanumab in Japan
Biogen and Eisai have jointly developed three experimental drugs for Alzheimer’s